- Company’s innovative cell selection product may dramatically reduce bone marrow transplantation risks
- Patient enrollment expected to begin in the next few weeks
TEL AVIV, Israel, Sept. 13, 2016 (GLOBE NEWSWIRE)—Cellect Biotechnology Ltd. (NASDAQ:APOP) (TASE:APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced that the Company has received the Israeli Ministry of Health’s approval to begin a Phase I/II clinical trial in leukemia patients. The trial, which Cellect expects will be initiated in a few weeks, is planned to be conducted in the bone marrow transplantation (“BMT”) unit of Rambam Hospital, and led by Clinical Assistant Professor, Zila Zuckerman, the Director of the unit. [Read more…]